MIMEDX GROUP, INC.

(MDXG)
  Report
Delayed Nasdaq  -  05/27 04:00:01 pm EDT
3.830 USD   +6.39%
05/26Leading Independent Proxy Advisory Firm ISS Recommends That MIMEDX Shareholders Vote 'FOR ALL' Of the Company's Proposals
AQ
05/25Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company's Proposals
AQ
05/24MIMEDX GROUP, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MiMedx Group, Inc. Provides Revenue Guidance for the Financial Year 2022

01/10/2022 | 08:00am EDT

MiMedx Group, Inc. provides revenue guidance for the financial year 2022. For the period, the company expects annual revenue growth of 11% to 14% in the Company’s continuing portfolio of products.


© S&P Capital IQ 2022
All news about MIMEDX GROUP, INC.
05/26Leading Independent Proxy Advisory Firm ISS Recommends That MIMEDX Shareholders Vote 'F..
AQ
05/25Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote &l..
AQ
05/24MIMEDX GROUP, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23MiMedx Group, Inc. - Leading Independent Proxy Advisory Firm Glass Lewis Recommends Tha..
AQ
05/20MiMedx Says Glass Lewis Recommends in Favor of Director Nominees, Say-on-Pay Proposal
MT
05/20Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders..
AQ
05/20Glass Lewis & Co Supports MiMedx Group Inc Nominees and Proposals
CI
05/18MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation
AQ
05/18MiMedx Group Files an Investor Presentation to Shareholders
CI
05/18Prescience Point Capital Management Calls on MiMedx to Confirm the Company Has Received..
PR
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2022 273 M - -
Net income 2022 -30,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -13,7x
Yield 2022 -
Capitalization 431 M 431 M -
Capi. / Sales 2022 1,58x
Capi. / Sales 2023 1,38x
Nbr of Employees 811
Free-Float 97,9%
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,83 $
Average target price 14,17 $
Spread / Average Target 270%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Scott M. Turner Vice President-Procurement
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-36.59%405
GILEAD SCIENCES, INC.-10.76%80 866
REGENERON PHARMACEUTICALS, INC.9.70%73 638
VERTEX PHARMACEUTICALS24.65%68 965
MODERNA, INC.-41.86%54 016
LONZA GROUP AG-28.07%42 292